RiBBON 1 and RiBBON 2: Phase III trials of bevacizumab with standard chemotherapy for metastatic breast cancer

Clinical Breast Cancer

Volumn 8, Issue 4, 2008, Pages 370-373

  O'Shaughnessy, Joyce A ^a   Brufsky, Adam M ^b  

^a BAYLOR UNIVERSITY MEDICAL CENTER   (United States)

^b UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

Author keywords

Angiogenesis; Monoclonal antibody; Vascular endothelial growth factor

Indexed keywords

ANTHRACYCLINE DERIVATIVE; BEVACIZUMAB; CAPECITABINE; CYCLOPHOSPHAMIDE; DOCETAXEL; DOXORUBICIN; EPIRUBICIN; FLUOROURACIL; GEMCITABINE; NAVELBINE; PACLITAXEL; PLACEBO; TAXANE DERIVATIVE;

ARTICLE; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER SURVIVAL; CLINICAL TRIAL; DRUG EFFICACY; DRUG RESPONSE; HUMAN; METASTATIC BREAST CANCER; MULTIPLE CYCLE TREATMENT; SURVIVAL TIME; TREATMENT OUTCOME;

EID: 53449087422     PISSN: 15268209     EISSN: None     Source Type: Journal    
DOI: 10.3816/CBC.2008.n.045     Document Type: Article

References (22)

1. O'Shaughnessy J. Extending survival with chemotherapy in metastatic breast cancer. Oncologist 2005; 10(suppl 3):20-9.
2. Hortobagyi GN, Theriault RL, Lipton A, et al. Long-term prevention of skeletal complications of metastatic breast cancer with pamidronate. Protocol 19 Aredia Breast Cancer Study Group. J Clin Oncol 1998; 16:2038-44.
3. Mariani G. New developments in the treatment of metastatic breast cancer:, from chemotherapy to biological therapy. Ann Oncol 2005; 16(suppl 2):ii191-4.
4. Perez EA, Suman VJ, Rowland KM, et al. Two concurrent phase II trials of paclitaxel/carboplatin/trastuzumab (weekly or every-3-week schedule) as first-line therapy in women with HER2-overexpressing metastatic breast cancer:. NCCTG study 983252. Clin Breast Cancer 2005; 6:425-32.
5. Marry M, Cognetti F, Maraninchi D, et al. Superior long-term survival benefits of trastuzumab plus docetaxel compared to docetaxel alone in patients with HER2-positive metastatic breast cancer: patients surviving more than 4 years in the M77001 study. Breast Cancer Res Treat 2006; 100(suppl 1):S101 (Abstract 2067).
6. Gonzalez-Angulo AM, Hennessy BT, Cristofanilli M, et al. Trends for inflammatory breast cancer: is survival improving? Breast Cancer Res Treat 2006; 100(suppl 1): (Abstract 6030).
7. Gerber HP, Ferrara N. Pharmacology and pharmacodynamics of bevacizumab as monotherapy or in combination with cytotoxic therapy in preclinical studies. Cancer Res 2005; 65:671-80.
8. Weidner N, Folkman J, Pozza F, et al. Tumor angiogenesis: a new significant and independent prognostic indicator in early-stage breast carcinoma. J Natl Cancer Inst 1992; 84:1875-87.
9. Willett CG, Boucher Y, di Tomaso E, et al. Direct evidence that the VEGF-specific antibody bevacizumab has antivascular effects in human rectal cancer. Nat Med 2004; 10:145-7.
10. Wildiers H, Guetens G, De BG, et al. Effect of antivascular endothelial growth factor treatment on the intratumoral uptake of CPT-11. Br J Cancer 2003; 88:1979-86.
11. Kim KJ, Li B, Winer J, et al. Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumour growth in vivo. Nature 1993; 362:841-.4.
12. Miller KD, Wang M, Gralow J, et al. A randomized phase III trial of paclitaxel versus paclitaxel plus bevacizumab as first-line therapy for locally recurrent or metastatic breast cancer:, a trial coordinated by the Eastern Cooperative Oncology Group (E2100). Breast Cancer Res Treat 2005; 94(suppl 1):S6 (Abstract 3).
13. Hurwitz H, Fehrenbacher L, Novotny W, et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 2004; 350:2335-42.
14. Sandier A, Gray R, Perry MC, et al. Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med 2006; 355:2542-50.
15. Giantonio B, Catalano PJ, Meropol NJ, et al. High-dose bevacizumab improves survival when combined with FOLFOX4 in previously treated advanced colorectal cancer. Results from the Eastern Cooperative Oncology Group (ECOG) study E3200. J Clin Oncol 2005; 23(16 suppl):1s (Abstract 2).
16. Burger RA, Sill M, Mark BJ, et al. Phase II trial of bevacizumab in persistent or recurrent epithelial ovarian cancer (EOC) or primary peritoneal cancer (PPC): a Gynecologic Oncology Group (GOG) study. J Clin Oncol 2005; 23(16 suppl):457s (Abstract 5009).
17. Herbst RS, Johnson DH, Mininberg E, et al. Phase I/II trial evaluating the anti-vascular endothelial growth factor monoclonal antibody bevacizumab in combination with the HER-1/epidermal growth factor receptor tyrosine kinase inhibitor erlotinib for patients with recurrent non-small-cell lung cancer. J Clin Oncol 2005; 23:2544-55.
18. Avastin (bevacizumab) [prescribing information]: South San Francisco, CA: Genentech; 2006.
19. Miller KD, Chap LI, Holmes FA, et al. Randomized phase III trial of capecitabine compared with bevacizumab plus capecitabine in patients with previously treated metastatic breast cancer. J Clin Oncol 2005; 23:792-9.
20. Miller K, Gradishar W, Moish C, et al. Capecitabine plus bevacizumab in first line metastatic breast cancer, an interim safety and efficacy report of the first phase of Xeloda plus Avastin 1st line metastatic breast cancer trial. Breast Cancer Res Treat 2006; 100(suppl 1):S103 (Abstract 2068).
21. Sledge G, Miller K, Moisa C, et al. Safety and efficacy of capecitabine (C) plus bevacizumab (B) as first-line in metastatic breast cancer. Presented at: the 43rd Annual Meeting of the American Society of Clinical Oncology; June 1-5, 2007; Chicago, FL. Available at: http://www.asco.org. Accessed: August 23, 2007.
22. Vredenburgh JJ, Desjardins A, Herndon JE, et al. Phase II trial of bevacizumab and irinotecan in recurrent malignant glioma. Clin Cancer Res 2007; 13:1253-9.